Premium
The Future of Migraine Prevention
Author(s) -
Cowan Robert P.
Publication year - 2018
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.13418
Subject(s) - migraine , context (archaeology) , calcitonin gene related peptide , class (philosophy) , mechanism (biology) , medicine , compliance (psychology) , calcitonin , intensive care medicine , psychology , psychiatry , computer science , history , social psychology , artificial intelligence , epistemology , receptor , philosophy , archaeology , neuropeptide
Barring unforeseen circumstances, we anticipate the arrival of the first mechanism‐specific class of molecules for migraine prevention in 2018. Despite many ground‐breaking advances in the field over the last several years, these agents, broadly identified as calcitonin gene‐related peptide‐based pharmaceuticals, have captured the imagination and attention of the lay press and much of the headache community. This paper will address the factors, both class‐specific and systems‐based, that are likely to affect the launch, access, compliance, and adherence related to this new class, as well as attempt to place these novel medications in context of the current state and anticipated changes in headache medicine.